MedTrace Logo

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

NCT02935153 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2019-06-25

No results posted yet for this study

Summary

The overall purpose of this study is to explore the therapeutic effect of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Malignant B-cell Derived Leukemia and Lymphoma.

Conditions

Interventions

BIOLOGICAL

Anti-CD22-CAR-transduced T cells

The first 3 enrolled patients will receive autologous-derived CD22-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.

Sponsors & Collaborators

  • Southwest Hospital, China

    lead OTHER

Principal Investigators

  • Cheng Qian, MD, PhD · Biotherapy Center of Southwest Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2019-10-31
Completion
2020-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02935153 on ClinicalTrials.gov